Roche will aim to tackle gene therapy challenges through Dyno deal
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche (ROG: SIX) to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases.
The partnership will see the utilization of artificial intelligence (AI), which is a key industry trend in the development of gene therapies in neurological disorders and could improve the vector properties and the delivery of gene therapies in the central nervous system (CNS), according to pharma analytics company GlobalData.
According to GlobalData’s report “Cell & Gene Therapies in CNS Disorders,” currently marketed gene therapies target rare or orphan monogenic diseases. Key opinion leaders (KOLs) previously interviewed by GlobalData noted that single-gene CNS disorders that have a known genetic mutation provide clear targets for gene therapies. However, many CNS disorders are not monogenic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze